Novartis Denied Summary Judgment in Tasigna Cancer Drug MDL




ORLANDO, Fla. — A Florida federal judge denied Novartis Pharmaceutical Corp.’s motion for summary judgment in the Tasigna MDL after refusing to exclude plaintiffs’ general causation expert, ruling that his methodology is reliable and that he drew a link between the cancer drug and irreversible atherosclerotic-related conditions.

In the Jan. 16 order, Judge Roy B. Dalton of the U.S. District Court for the Middle District of Florida did rule, however, that Dr. Sonal Singh may not opine that Tasigna causes atherosclerosis characterized as “severe,” “rapidly progressive,” or “treatment-resistant.”

Plaintiffs accuse Novartis of failing to warn that Tasigna nilotinib)— which …






UPCOMING CONFERENCES




HarrisMartin's New Jersey Asbestos Litigation Conference

March 01, 2024 - New Brunswick, NJ
Hyatt Regency New Brunswick

MORE DETAILS



HarrisMartin's Ozempic MDL Conference: Updates from the Status Hearing

March 15, 2024 - Philadelphia, PA
Kimpton Hotel Monaco Philadelphia

MORE DETAILS